GSK looks to expand into MM subsets after submitting first anti-BCMA BLA

GSK hopes being the first to seek approval will position ADC belantamab mafodotin in the BCMA market

GSK is the first company out of the gate with a regulatory submission for a BCMA-targeted therapy. The ADC’s most recent response rates are lower than many programs from competing modalities against the same target reported this month, but the company is using its head start to rapidly move into early-line settings.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported full data for the pivotal DREAMM-2 trial of its antibody-drug conjugate belantamab mafodotin (GSK2857916)

Read the full 708 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers